EGFR and neoplasm: Last but not least, the acceleration of tumor growth can also be found in patients receiving traditional immunotherapy, including the adjuvant IFN‐α154 and anti‐CD20 antibody,155, 156 or targeted therapy, such as RAF inhibitors157 and BRAF inhibitors,158, 159 or in patients with discontinuation of ALK‐tyrosine kinase inhibitors,160 EGFR‐tyrosine kinase inhibitors,161 and VEGFR‐tyrosine kinase inhibitors.162